NasdaqGS:IONSBiotechs
Ionis Pharmaceuticals (IONS) Trailing US$381.4m Loss Tests Bullish Profitability Narratives Ahead Of Q1 2026
Ionis Pharmaceuticals (IONS) opened 2026 with Q1 results that keep the focus firmly on its path to profitability, following 2025 figures that included Q4 revenue of US$203.3 million, a basic EPS loss of US$1.42, and a full year of trailing twelve month revenue of US$943.7 million against a net loss of US$381.4 million. Over recent quarters, the company has seen revenue move from US$131.6 million in Q1 2025 to US$452.0 million in Q2 2025, US$156.7 million in Q3 2025, and US$203.3 million in Q4...